Daniel A Cartwright Net Worth

The estimated Net Worth of Daniel A Cartwright is at least $71.1 Tisíc dollars as of 6 December 2018. Daniel Cartwright owns over 40,000 units of TherapeuticsMD Inc stock worth over $71,116 and over the last 12 years Daniel sold TXMD stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Daniel Cartwright TXMD stock SEC Form 4 insiders trading

Daniel has made over 6 trades of the TherapeuticsMD Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Daniel exercised 40,000 units of TXMD stock worth $15,200 on 6 December 2018.

The largest trade Daniel's ever made was exercising 40,000 units of TherapeuticsMD Inc stock on 6 December 2018 worth over $15,200. On average, Daniel trades about 12,632 units every 78 days since 2012. As of 6 December 2018 Daniel still owns at least 40,000 units of TherapeuticsMD Inc stock.

You can see the complete history of Daniel Cartwright stock trades at the bottom of the page.

What's Daniel Cartwright's mailing address?

Daniel's mailing address filed with the SEC is 951 YAMATO ROAD, SUITE 220, BOCA RATON, FL, 33431.

Insiders trading at TherapeuticsMD Inc

Over the last 13 years, insiders at TherapeuticsMD Inc have traded over $21,656,853 worth of TherapeuticsMD Inc stock and bought 721,732 units worth $2,299,099 . The most active insiders traders include Cooper C. Collins, Brian Bernick a Robert G Finizio. On average, TherapeuticsMD Inc executives and independent directors trade stock every 29 days with the average trade being worth of $272,607. The most recent stock trade was executed by John C.K. Iv Milligan on 25 October 2019, trading 72,000 units of TXMD stock currently worth $198,000.

What does TherapeuticsMD Inc do?

therapeuticsmd, inc. is an innovative pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their health care issues. we create products to address the unique changes and challenges women experience through every stage of their lives. with momentum fueled by the needs of our customers, we combine entrepreneurial spirit and clinical expertise to develop innovative solutions designed to go beyond what is presently available. this includes a variety of therapies in our pipeline, along with prescription prenatal vitamins under the vitamedmd® and bocagreenmd® brands. see our community guidelines: https://www.therapeuticsmd.com/social-media-community-guidelines

Complete history of Daniel Cartwright stock trades at TherapeuticsMD a TherapeuticsMD Inc

TherapeuticsMD Inc executives and stock owners

TherapeuticsMD Inc executives and other stock owners filed with the SEC include:

• John Milligan,
  President, Secretary
• Brian Bernick,
  Co-Founder
• Robert Finizio,
  Chief Executive Officer and Director
• Robert G. Finizio,
  Co-Founder & Vice Chair
• Mitchell Krassan,
  Chief Strategy and Performance Officer
• John C. K. Milligan IV,
  Chief Exec. Officer of VitaCare Prescription Services
• Michael Donegan,
  Vice President - Finance
• Tommy Thompson,
  Independent Chairman of the Board
• Cooper Collins,
  Independent Director
• J. Martin Carroll,
  Independent Director
• Angus Russell,
  Independent Director
• Jules Musing,
  Independent Director
• Dr. Brian A. Bernick,
  Co-Founder & Chief Scientific Officer
• Nichol Ochsner,
  Vice President, Investor Relations
• Gail Naughton,
  Independent Director
• Karen Ling,
  Independent Director
• Paul Bisaro,
  Independent Director
• Bharat Warrier,
  Chief Manufacturing Officer
• Sebastian Mirkin,
  Chief Medical Officer
• Dawn Halkuff,
  Chief Commercial Officer
• Marlan Walker,
  General Counsel
• John Knighton,
  Chief Compliance Officer
• Adam Miller,
  Chief Information Officer
• James D'Arecca,
  Chief Financial Officer
• Julia M. Amadio,
  Chief Product Officer
• Mitchell L. Krassan,
  Exec. VP and Chief Strategy & Performance Officer
• Chris Gish,
  Sr. VP of Sales
• Michael Donegan,
  Chief Accounting Officer & VP of Fin.
• James C. D'Arecca,
  Chief Financial Officer
• Hugh O'Dowd M.B.A.,
  Pres, CEO & Director
• Robert V Jr La Penta,
  Director
• Nicholas Segal,
  Director
• Jane F Barlow,
  Director
• Daniel A Cartwright,
  Chief Financial Officer
• Randall S Stanicky,
  Director
• Samuel A Greco,
  Director